https://www.selleckchem.com/pr....oducts/p5091-p005091
Results This study included 494 patients (median age, 62 years [IQR, 56-71 years]; 401 men). Originally, 123 patients were classified as BCLC B with mOS of 24.3 months (95% CI 21.4, 32.9) and 371 patients as BCLC C with mOS of 11.9 months (95% CI 10.5, 14.8). The mOS of all included patients (including the BCLC B and C groups) was 15 months (95% CI 12.3, 17.2). A total of 152 patients with BCLC C tumors were restratified into a new BCLC Bn class, in which the mOS was then 25.1 months (95% CI 21.8, 29.7; P less then .001). The mOS
Like
Comment
Share
